Drug · DIN 02418320
LEMTRADA
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 27, 2026; first marketed January 29, 2014.
- Drug Identification Number (DIN)
- 02418320
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Schedule D; Prescription
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Alemtuzumab L04AG06
- Class
- Human
- Record last updated
- October 9, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ALEMTUZUMAB | 12 MG | 1.2 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- April 19, 2024: NOC 33110New Drug Submission (NDS) · Administrative - Change in Product Ownership
- December 12, 2013: NOC 15031New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “lemtrada”. A notice may cover another product or only some lots: read it to see what it covers.
- LEMTRADA (alemtuzumab) - Risk of Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Associated Serious Cardiovascular ReactionsOctober 15, 2019 · Drugs · Product safety